A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma

Wei Sun1,2,4, Fan-Qin Wei1,2,3,4, Wei-Jin Li1,2,4, Jia-Wei Wei1,2, Hua Zhong1,2, Yi-Hui Wen1,2, Wen-Bin Lei1,2, Lin Chen1,2, Hang Li1,2, Han-Qing Lin1,2, Muhammad Iqbal1,2 and Wei-Ping Wen*,1,2

1Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; 2Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, Guangzhou 510080, China and 3Department of Otorhinolaryngology Head and Neck Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510655, China

Keywords: regulatory T cells; macrophages; laryngeal squamous cell carcinoma

Background: Foxp3⁺ regulatory T (Treg) cells and M2 macrophages are associated with increased tumour progression. However, the interaction between Treg cells and M2 macrophages remains unclear.

Methods: The expression of FoxP3 and CD163 was detected by immunohistochemistry in 65 cases of laryngeal squamous cell carcinoma (LSCC). In vitro, the generation of activated Treg (aTreg) cells and M2 macrophages by interactions with their precursor cells were analysed by flow cytometry and ELISA. In vivo, the antitumour effects were assessed by combined targeting aTreg cells and M2 macrophages, and intratumoural immunocytes were analysed by flow cytometry.

Results: In LSCC tissue, accumulation of aTreg cells and M2 macrophages predicted a poor prognosis and were positively associated with each other. In vitro, aTreg cells were induced from CD4⁺CD25⁻ T cells by cancer cell-activated M2-like macrophages. Consequently, these aTreg cells skewed the differentiation of monocytes towards an M2-like phenotype, thereby forming a positive-feedback loop. Combined targeting aTreg cells and M2 macrophages led to potent antitumour immunity in vivo.

Conclusions: The positive-feedback loop between aTreg cells and M2 macrophages is essential to maintain or promote immunosuppression in the tumour microenvironment and may be a potential therapeutic target to inhibit tumour progression.

Immunotherapy, including anticancer vaccination and adoptive transfer of tumour-specific cytotoxic T lymphocytes, has been considered as a promising treatment for head and neck squamous cell carcinoma (HNSCC), although its effects on tumour regression remain limited (Schuler et al, 2014; Li et al, 2015). The inefficacy of such therapies implies that head and neck carcinoma has

*Correspondence: Professor W-P Wen; E-mail: wenwp@mail.sysu.edu.cn
†These authors contributed equally to this work.

Received 21 May 2017; revised 8 August 2017; accepted 24 August 2017; published online 26 September 2017

© 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
developed diverse strategies to evade tumour-specific immunity (Ferris, 2015).

Studies show that regulatory T (Treg) cells and M2 macrophages are crucial players in immune tolerance (Mantovani et al, 2002; Khazaie and von Boehmer, 2006; Zou, 2006; Alhamarneh et al, 2008; Mantovani and Locati, 2013). Recently, to evoke antitumour immunity in vivo, we blocked tumour trafficking of CD45RA Foxp3high activated Treg (aTreg) cells using a CCR4 antagonist, which led to inhibition of tumour growth and prolonged survival (Sun et al, 2014, 2015, 2016). However, the effect of targeting a single immunosuppressive population is not satisfactory. This prompted us to employ a combined strategy targeting both aTreg cells and M2 macrophages and further investigate their interactions.

In this study, we evaluated the clinical importance of tumour-infiltrating aTreg cells and M2 macrophages in laryngeal squamous cell carcinoma (LSCC) patients and confirmed their positive correlation. We demonstrated that cancer cell-activated M2-like macrophages induced aTreg cells from CD4+CD25+ T cells in vitro. Reciprocally, the generated aTreg cells skewed the differentiation of monocytes towards the M2-like phenotype, forming a positive-feedback loop. Blockade of aTreg cell trafficking combined with depletion of tissue macrophages reduced both intratumoural aTreg cells and M2 macrophages to the maximum extent and significantly enhanced antitumour immunity in experimental mice.

**MATERIALS AND METHODS**

**Immunohistochemical analysis.** The main clinical and pathological characteristics of LSCC patients are presented in Supplementary Table S1. Clinical staging and the anatomical site of tumours were assessed according to the sixth edition of the Union for International Cancer Control (UICC 2008) tumour-node-metastasis classification of malignant tumours. Paraffin-embedded, formalin-fixed 4 µm-thick tissue sections were processed for immunohistochemical staining with anti-Foxp3 (Ab22510, IgG1, 1 : 300 dilution, Abcam, Cambridge, MA, USA), anti-CD163 (Ab87099, IgG, 1 : 80 dilution, Abcam) and anti-p16/INK4a (Clone EPR1473, 1 : 250 dilution, Epitomics Inc., Burlingame, CA, USA) antibodies. The antibodies of Foxp3+ or CD163+ cells was evaluated quantitatively by the mean count of four standard conditions. Xiu Liu (West China Hospital, China). Cells were cultured under specified otherwise.

**Cell lines and animals.** Human LSCC cell lines (SNU46 and SNU899) and a nasopharyngeal squamous cell carcinoma (NPSCC) cell line (HONE1) were kindly provided by Professor Ja-Lok Ku (Seoul National University College of Medicine, South Korea). Tumour culture supernatants (TSNs) were prepared as specified previously (Miyara et al, 2009). Foxp3lowCD45RA+ cells, which were CD25++ (I), Foxp3highCD45RA- cells, which were CD25+++ (II), and Foxp3lowCD45RA- cells, which were CD25++ (III), were prepared by sorting CD25+ and CD45RA+, CD25+++ and CD45RA-, and CD25++ and CD45RA-, respectively.

**Cell co-culture.** Cells were co-cultured in RPMI 1640 medium supplemented with 1% penicillin/streptomycin, and 10% heat-inactivated foetal calf serum. For Treg cell generation, 1 x 106 autologous macrophages were co-cultured with 2 x 106 CD4+ CD14- depleted PBMCs in the presence of 0.5 µg ml⁻¹ anti-CD3 mAb or with 1 x 106 CD4+CD25+ T cells in the presence of 2 µg ml⁻¹ anti-CD3 mAb plus 1 µg ml⁻¹ anti-CD28 mAb for 4 days. For macrophage differentiation, CD4+ cells were seeded in a round bottom 96-well plate at 2 x 10⁶ cells per well. CD4+CD25+ T cells and the three Treg subsets were added to autologous CD4+ cells at a ratio of 1:2 and co-cultured for 40 h in the presence of 50 ng ml⁻¹ anti-CD3 mAb with or without 20% TSN from SNU899 cells.

For neutralisation experiments, neutralising antibodies against TGF-β1 (5 µg ml⁻¹, mouse IgG1, clone 9016), IL-10 (5 µg ml⁻¹, goat IgG), IL-4 (5 µg ml⁻¹, mouse IgG1, clone 3007), or IL-13 (5 µg ml⁻¹, mouse IgG1, clone 32116) and isotype controls (mouse IgG1 or goat IgG) were added at the start of the co-culture. All experiments were approved by the Institutional Animal Studies Committee and conducted in accordance with Institutional Animal Care and Use Committee guidelines.

**Cell preparation.** The study protocol was approved by The Ethics Committee of The First Affiliated Hospital of Sun Yat-Sen University and used for research purposes only (Approval No. 2012-349). Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors by Ficoll density gradient centrifugation. CD14- cells were isolated from PBMCs using CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured with or without 20% TSN for 6 days to obtain macrophages.

To isolate CD4+CD25− T cells and Treg subsets, cells were stained with anti-hCD4-FITC, anti-hCD25-APC, and anti-hCD45RA-eFluor 450 (eBioscience, San Diego, CA, USA) antibodies, and sorted using a BD Influx cell sorter (BD Biosciences). Three Treg subsets were prepared as live cells as described previously (Miyara et al, 2009). Foxp3lowCD45RA+ cells, which were CD25++ (I), Foxp3highCD45RA- cells, which were CD25+++ (II), and Foxp3lowCD45RA- cells, which were CD25++ (III), were prepared by sorting CD25+ and CD45RA+, CD25+++ and CD45RA-, and CD25++ and CD45RA-, respectively.

**Flow cytometric analysis.** To determine the phenotype of macrophages, the following antibodies were used: anti-hCD163-APC, anti-hCD206-Alexa Fluor 488, anti-hHLA-DR-eFluor 450, anti-hCD86-PE, and anti-hCD80-PE-Cy5. To determine the frequency of the three distinct Treg subsets, the following antibodies were used: anti-hCD4-FITC, anti-hCD25-APC, and anti-hCD45RA-eFluor 450 for surface staining; anti-hFoxp3-APC for intracellular staining.

For the intracellular cytokine assay, the sorted CD4+CD25− T cells and each Treg subset were stimulated with a cocktail of phorbol 12-myristate 13-acetate (PMA), ionomycin, and Golgi stop (brefeldin A and monensin; eBioscience) for 5 h. Then, we performed intracellular staining using anti-hIL-4-PE-Cy7, anti-hIL-10-PerCP-eFluor 710, anti-hIL-13-PE (Sony Biotechnology, Inc, San Jose, CA, USA), and anti-hIFN-γ-APC-eFluor 780 antibodies. All antibodies were purchased from eBioscience unless specified otherwise.

**Cytokine detection.** The concentrations of IL-10, IL-6, IL-12p70, TNF-α, IL-4, IL-5, IL-13, IL-2, IFN-γ, and TGF-β1 in culture supernatants was determined using ELISA kits according to the manufacturer’s instructions (IL-2, IFN-γ, and TNF-α from R&D Systems; others from RayBiotech, Inc, Norcross, GA, USA).

**Combined targeting of aTreg cells and M2 macrophages in vivo.** Twenty mice were randomly and equally divided into four groups and ear tagged prior to treatment. On day 0, 1 x 10⁶ tumour cells were injected subcutaneously into the right flank. A CCR4 antagonist (87.5 µg; TOCRIS, Minneapolis, MN, USA; Sun et al, 2016), GdCl3 (0.2 mg; Sigma-Aldrich, Saint Louis, MO, USA; Jiang et al, 2005), or CCR4 antagonist + GdCl3 were injected...
intrapertioneally three times per week for 3 weeks from day 5 after tumour cell injection. A group of five mice for the saline control was set in parallel. Tumour size was measured every 4 days using fine calipers. Tumour volumes were calculated as length × (width)² × 0.5. All mice were killed at 24 h after the last injection.

After killing the mice, tumours and spleens were isolated and prepared as single cell suspensions. Mononuclear cells were isolated using a Ficoll density gradient and analysed for aTreg cells, M2 macrophages, CD4⁺ and CD8⁺ T cells, and Th1 cytokines by flow cytometry using anti-mouse CD4-eFluor 450, anti-mouse CD8-Alexa Fluor 700, anti-mouse CD25-APC, anti-mouse CD45RA-FITC (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-mouse CD206-PE-Cy7 (Sony Biotechnology, Inc), anti-mouse F4/80-PE-Cy5.5, anti-mouse FoxP3-PE, anti-mouse IL-2-PE, anti-mouse IFN-γ-PE-Cy5.5, and anti-mouse TNF-α-PE-Cy7 antibodies, and a fixation/permeabilisation kit. Antibodies were purchased from eBioscience unless specified otherwise. Immunohistochemical staining of CD3 (Ab16669, IgG, 1:100 dilution, Abcam) was also performed to assess intratumoural CD3⁺ T cells. Another randomly divided four groups of mice were used for survival analysis. Observation was aborted on day 50.

Statistical analysis. All statistical analyses were performed with SPSS for Windows version 13.0 (IBM, Chicago, IL, USA). For Foxp3 and CD163, the cutoff to define the subgroups was the median value. Analysis of the correlation between variables was conducted using Spearman’s rank coefficient tests. Survival variables were estimated using the Kaplan–Meier method and compared using log-rank tests. Differences between groups were assessed using the Mann–Whitney U-test, Student’s t-test, or Kruskal–Wallis test. Multivariate analysis using the Cox proportional hazard model was used to determine the influence of each variable, when adjusted to the others, on overall survival. P-values of < 0.05 were considered as statistically significant.

RESULTS

Accumulation of aTreg cells and M2 macrophages is positively associated with each other in LSCC tissue and predicts poor survival. We first examined the prevalence of tumour-infiltrating aTreg cells and M2 macrophages in 65 patients with LSCC, the common type of HNSCC (Supplementary Table S1). Immunohistochemical staining of Foxp3 and CD163 was performed in paraffin-embedded tissues. Both Foxp3⁺ aTreg cells and CD163⁺ macrophages had substantially infiltrated into the stroma, but scarcely into tumour sites (Figure 1A). To determine the clinical importance of Foxp3⁺ aTreg cells and CD163⁺ macrophages in stromal of tumours, we analysed their associations with clinico-pathological characteristics and overall survival. The levels of Foxp3⁺ aTreg cell and CD163⁺ macrophage infiltration in patients at late clinical stages (III and IV) were significantly higher than those at early clinical stages (I and II; P < 0.01 and P < 0.05, respectively; Figure 1B and C) (Supplementary Table S2). Expression of Foxp3 and CD163 increased with the pathological stage, although no significant difference was found in Foxp3 expression (Figure 1D and E; Supplementary Table S2). Patients with high numbers of intratumoural Foxp3⁺ aTreg cells/CD163⁺ macrophages had shorter overall survival (medians: 74/78 months) than those with low numbers of Foxp3⁺ aTreg cells/CD163⁺ macrophages (medians: 94/90 months; Figure 1F and G). Furthermore, there was a significant difference between the group with high expression of both Foxp3 and CD163 and the group with low expression of both Foxp3 and CD163 (medians: 71, 87, and 94 months, respectively; Figure 1H). These data supported important roles of both aTreg cells and M2 macrophages in accelerating tumour progression and predicting poor survival. In a Cox Multivariate analysis (Supplementary Table S3), clinical stage, nodal status, tobacco and alcohol consumption were associated with overall survival. The presence of high numbers of intratumoural Foxp3⁺ aTreg cells in combination with high numbers of intratumoural CD163⁺ macrophages was an independent prognostic marker for overall survival, while the HPV status had no independent prognostic value (Supplementary Figure S1).

Moreover, Spearman’s rank correlation coefficient was calculated to assess the relationship between Foxp3⁺ aTreg cells and CD163⁺ macrophages. The densities of the two markers were positively correlated with each other in LSCC specimens (Figure 1I). This quantitative relationship encouraged us to further investigate their biological interactions.

Macrophages exposed to tumour culture supernatant from LSCC-derived cell lines exhibit an M2-like phenotype and augment the Foxp3⁺ Treg population in peripheral blood mononuclear cells. To investigate whether cancer cells with a distinct epithelial phenotype have a different ability to activate macrophages, we cultured freshly isolated human mononocytes in medium with 25% tumour culture supernatant (TSN) from a nasopharyngeal carcinoma cell line (HONE1) or laryngeal carcinoma cell lines (SNU46 or SNU899) for 6 days to obtain macrophages. Figure 2A shows that, relative to untreated macrophages, TSN-treated macrophages displayed strong up-regulation of typical M2 macrophage markers CD163 and CD206 (data not shown) and reduced expression of HLA-DR, CD86, and CD80, which are associated with immunosuppression. They also produced higher amounts of an M2 macrophage cytokine (interleukin (IL)-10) and lower levels of M1 macrophage cytokines (tumour necrosis factor-ζ (TNF-ζ), IL-6, and IL-12p70) (Figure 2B), indicating that macrophages were activated to an ‘M2-like state’ by TSN. Moreover, the level of activation by TSN from SNU899 cells, as measured by cytokine production and surface marker expression of M2 macrophages, was the highest among all groups, suggesting that SNU899-derived TSN was a strong macrophage activator.

To determine whether these activated macrophages induced Foxp3⁺ Treg cells, they were co-cultured with autologous peripheral blood mononuclear cells (PBMCs). Consistent with the changes in surface markers and cytokines, more Foxp3⁺ Treg cells were derived from macrophages treated with TSN from SNU899 (MφSNU899: 82.0 ± 4.7%) than untreated macrophages (Mφ: 36.5 ± 2.9%) or those treated with TSNs from other HNSCC cell lines (MφSNU46: 68.2 ± 3.2%; MφPHONE1: 64.0 ± 3.4%; Figure 2C). In addition, to investigate the overall effect of macrophages on the immune response, we examined cytokines in the co-cultures by immunosorbent assays (ELISAs). The levels of Th2 cytokines (IL-5 and IL-13) were correspondingly increased in the culture supernatants (Figure 2D), while the production of Th1 cytokines (interferon-γ (IFN-γ), IL-2, and TNF-α) was suppressed to undetectable levels (data not shown), implying that the TSN-exposed macrophages mediated a tumour-promoting effect.

Taken together, these results indicate that macrophages activated by TSN from LSCC cell lines have an M2-like phenotype and may serve as an important initiator of Treg cell induction.

TSN-exposed M2-like macrophages induce an aTreg cell subset from CD4⁺ CD25⁻ T cells. To eliminate the possibility that TSN-exposed macrophages were merely expanding the pre-existing naturally occurring Treg cells present at the initiation of culture, we sorted autologous CD4⁺ CD25⁻ T cells as responder cells before adding macrophages (n = 3). A clear conversion from CD4⁺ CD25⁻ Foxp3⁺ T cells to CD4⁺ CD25⁺ Foxp3⁺ Treg cells was observed by flow cytometric analysis (Figure 3Aa and Ab). We further identified the functionally distinct subsets of these newly generated Treg cells (Figure 3Ac), because Treg cells with a
Figure 1. Clinical implications and correlation of tumour-infiltrating aTreg cells and M2 macrophages. (A) Representative images of immunohistochemical staining of Foxp3+ and CD163+ cells: Foxp3 expression in the tumour (a), low and high Foxp3 expression in the stroma (b and c), CD163 expression in the tumour (d), low and high CD163 expression in the stroma (e and f). Positive cells are stained brown (×400 magnification). Lower panels are magnified images of the boxed areas in the corresponding upper panels. (B and C) Levels of Foxp3+ and CD163+ cell infiltration in patients with early stage tumours were lower than those in patients with late stage tumours. Statistical differences between the two groups were analysed using the Mann-Whitney U-test. (D and E) Comparison of the levels of Foxp3+ and CD163+ cell infiltration between three groups with different degrees of differentiation. Statistical differences were analysed using the Kruskal-Wallis test. (F–H) Kaplan-Meier analysis of overall survival in terms of intratumoural Foxp3+ aTreg cells (F), CD163+ macrophages (G), and their combination (H) in LSCC samples (n=65). High numbers of Foxp3+ aTreg cells with concomitant high numbers of CD163+ macrophages were associated with poor survival. (I) Spearman’s rank correlation coefficient was calculated to assess the relationship between Foxp3+ and CD163+ cells. The density of CD163+ macrophages was positively correlated with that of Foxp3+ aTreg cells in tumour tissue.
phenotype of CD45RA^+ Foxp3^low or CD45RA^− Foxp3^high can exhibit immunosuppressive functions (Miyara et al, 2009). We found a dominant increase in CD45RA^− Foxp3^high aTreg cells of the suppressive Treg subsets (Figure 3B and C), indicating that the Treg cells induced by M2-like macrophages may directly mediate an inhibitory effect on tumour immunity.

To determine the nature of the soluble factors involved in the induction of aTreg cells, neutralising antibodies against transforming growth factor (TGF)-β1, IL-10, or TGF-β1/IL-10 were added to the cocultures. Our results showed that neutralising IL-10 partially attenuated the typical increase in aTreg cell frequency resulting from co-culture of MφSNU899 with CD4^+ CD25^− T cells, whereas blocking TGF-β1 had no significant effect (Figure 3D and E). Therefore, IL-10 attributed to MφSNU899 was involved in the induction of aTreg cells from CD4^+ CD25^− T cells.

aTreg cells skew the differentiation of monocytes toward M2 macrophages in the TSN. To investigate whether the MφSNU899-induced Treg subsets skew the differentiation of monocytes to M2-like macrophages, CD14^+ monocytes were cultured alone, with CD4^+ CD25^− T cells, or with each sorted Treg subset (n = 5). An anti-CD3 monoclonal antibody (mAb) was present in all
Figure 3. TSN-exposed M2-like macrophages significantly induce aTreg cells from CD4+ CD25+ T cells. CD14+ monocytes were cultured with TSNs from a laryngeal carcinoma cell line (MφSNU899), followed by coculture with autologous CD4+ CD25+ T cells for 4 days with or without neutralising mAbs against TGFβ-1, IL-10, or TGFβ-1/IL-10 in the presence of 2μg/ml-1 anti-CD3 mAb plus 1μg/ml-1 anti-CD28 mAb. (A) Foxp3+ CD25+ Treg cells were actively induced by MφSNU899 from CD25-depleted cells (a and b). Flow cytometry of each subset of induced Treg cells (c). (B) The frequency of the induced Treg cells from CD4+ CD25+ T cells was compared with that of the pre-existing naturally occurring Treg cells in autologous CD4+ T cells. Representative plots of the frequency of Fr. I and Fr. II Treg cells among CD4+ T cells and in the co-culture of MφSNU899 with CD4+ CD25+ T cells. (C) Statistical analysis showed that the percentage of Fr. II aTreg cells was markedly increased in the co-culture of MφSNU899 with CD4+ CD25+ T cells (mean ± s.d., n = 3; **P<0.01 compared with CD4+ T cells). (D) Representative plots of the frequency of Fr. II aTreg cells assessed after 4 days of co-culture with or without the indicated neutralising mAbs. (E) A histogram revealed that the increase of Fr. II aTreg cells was partially blocked by an anti-IL-10 antibody (mean ± s.d., n = 3; *P<0.05). (A–E) I, CD45RA+ Foxp3low resting Treg (rTreg) cells; II, CD45RA– Foxp3high activated Treg (aTreg) cells; III, CD45RA– Foxp3low CD4+ T cells. Both of Fr. I and Fr. II were immunosuppressive, and Fr. III was non-suppressive. TSNs, tumour culture supernatants.
conditions to stimulate the T cells. After 40 h, cells were collected for flow cytometry. Interestingly, compared with control monocytes, monocytes co-cultured with aTreg cells, but not CD45RA⁺Foxp3lowCD4⁺ resting Treg (rTreg) cells or CD45RA⁻Foxp3lowCD4⁺ T cells, displayed strong up-regulation of the typical M2 macrophage marker CD163. In addition, reduced expression of HLA-DR, CD86, and CD80 was observed (Figure 4A). The differences in the modulation of monocyte/macrophage functions may lie in the distinct cytokine patterns of these Treg subsets. Of note is that the aTreg subset was the highest producer of IL-10, CD45RA⁻Foxp3lowCD4⁺ T cells produced high amounts of IL-4, IL-13, and IFN-γ, while the rTreg subset was a poor producer of these cytokines (Figure 4B and C). To validate the cytokine effect on the aTreg cell-M2 macrophage induction, neutralising antibodies against IL-10, IL-4/IL-13, or IL-10/IL-4/IL-13 were added to the co-cultures. Unsurprisingly, neutralising IL-10 was sufficient to

---

**Figure 4.** aTreg cells skew the differentiation of monocytes partly mediated via IL-10 towards M2 macrophages in the TSN. (A) Monocytes were cultured without T cells, with CD4⁺CD25⁻ cells, or with each sorted Treg subset in the presence of an anti-CD3 mAb (50 ng ml⁻¹). Monocyte phenotypes were assessed after 40 h of culture by flow cytometry (average mean fluorescence intensity, MFI ± s.e.m., n = 5; P < 0.05; Δ, no T vs CD25⁻; Θ, no T vs I/II/III; #, CD25⁻ vs I/II/III). (B) Production of IL-4, IL-10, IL-13, and IFN-γ by CD4⁺CD25⁻ T cells and each Treg subset after stimulation with PMA + ionomycin. The percentage of cytokine-secreting cells in each cell population is shown. Data are representative of three separate experiments. (C) The histogram represents the cytokine expression profiles of CD25⁻ T cells and each Treg subset (means ± s.d., n = 3). (D) Monocytes and Fr. II aTreg cells were co-cultured with or without neutralising mAbs against IL-10, IL-4/IL-13, or IL-10/IL-4/IL-13. CD163 expression was assessed by flow cytometry at 40 h after the start of the co-culture (MFI ± s.e.m., n = 3; **P < 0.01). (E) Monocytes were cultured for 40 h without or with Fr. II aTreg cells in the absence or presence of TSN from the SNU899 laryngeal carcinoma cell line. Monocytes cultured with medium alone were set as the control. CD163 and HLA-DR expression is shown. (MFI ± s.e.m., n = 3; *P < 0.05, **P < 0.01). (A–E) I, CD45RA⁺Foxp3low resting Treg (rTreg) cells; II, CD45RA⁻Foxp3high activated Treg (aTreg) cells; III, CD45RA⁻Foxp3lowCD4⁺ T cells. TSNs, tumour culture supernatants.
reverse the upregulation of CD163 and the down-regulation of HLA-DR (data not shown), whereas neutralising IL-4/IL-13 had no effect (Figure 4D).

Next, to examine this aTreg-mediated effect on monocyte/macrophage functions in a tumour context, we added SNU899 cell-derived TNs to the co-cultures. Interestingly, CD163 expression was increased further and accompanied by a further decline in the HLA-DR level. As a control, TSN alone could only induce a very small increase in the expression of CD163 and a marginal decrease in the HLA-DR level (Figure 4E). These data imply that the tumour cell induced soluble microenvironment may enhance the ability of aTreg cells to convert monocytes into M2 macrophages.

The positive-feedback loop between tumour-infiltrating aTreg cells and M2 macrophages contributes to immunosuppression. Because TSN-exposed M2-like macrophages induced aTreg cells that in turn promoted induction of M2 macrophages in vitro, we investigated the feedback relationship between aTreg cells and M2 macrophages in vivo. After administration of a C–C chemokine receptor type 4 (CCR4) antagonist to specifically block tumour recruitment of aTreg cells, we observed that the percentage of tumour-infiltrating M2 macrophages was decreased by 27.17% (Figures 5Ab and Bb; 61.1 + 4.10% in control vs. 44.50 ± 3.54% in CCR4 antagonist, n = 5, paired t-test, P < 0.05). In turn, treatment with gadolinium chloride (GdCl3) to deplete tissue macrophages attenuated the proportion of aTreg cells by 28.20% (Figures 5Aa and Ba; 30.85 ± 1.91% in control vs. 22.15 ± 2.05% in GdCl3, n = 5, paired t-test, P < 0.05), suggesting mutually dependent decreases or increases of aTreg cells and M2 macrophages in tumours.

Both aTreg cells and M2 macrophages have a key role in subversion of anti-tumour immunity. We found that targeting aTreg cells or M2 macrophages resulted in expansion of CD4+ and CD8+ T cells in tumours (Figures 5Ac, Bc and Bd). Moreover, T cells in CCR4 antagonist- and GdCl3-treated groups secreted higher amounts of IFN-γ, IL-2, and TNF-α than T cells in the control group (Figure 5C and D), which is consistent with previous reports (Noy and Pollard, 2014; Sun et al., 2016). Therefore, the positive-feedback loop between aTreg cells and M2 macrophages by promoting induction of each cell type may significantly contribute to immunosuppression in the TME.

Combined targeting aTreg cells and M2 macrophages hampers their positive-feedback loop and evokes a potent antitumour immune response in vivo. This aTreg cell-M2 macrophage loop by enhancing tumour-induced immunosuppression represents a bar to successful immunotherapy. Therefore, combined targeting of the generation of the two suppressive cell populations is a desirable goal in chemo- and immuno-therapeutic approaches. We first observed that tumour growth was significantly inhibited and the survival of mice was significantly prolonged in the CCR4 antagonist + GdCl3-treated group compared with the PBS control group and single-treated groups (Figure 6A–C; Supplementary Table S4). The weight of tumours, which were excised at 28 days after tumour cell injection, was significantly lower in the combined treatment group than in other groups (Figure 6D and E; Supplementary Table S4), whereas spleen weights were higher in this group (Figure 6F; Supplementary Table S4). These results suggest the effectiveness and practicability of this combined strategy targeting both aTreg cells and M2 macrophages.

To investigate whether the inhibition of tumour growth in the combined treatment group was associated with T-cell-mediated antitumour immunity, we analysed the composition of T cells that had infiltrated into the tumour tissues of mice. Immunohistochemical staining and flow cytometric analysis showed that the frequencies of CD3+ CD4+, and CD8+ T cells and Th1 cells were significantly higher in tumour tissues of the combined treatment group than in those of the other groups (Figure 6G and H and Figure 5Ac, Bc–d, C and D). These results indicated that the CCR4 antagonist + GdCl3 treatment evoked the most potent T-cell responses in the TME. Notably, this treatment had no obvious effect on T cells in the spleen (Figure 6I), which supports its potential therapeutic implications.

We hypothesised that the combined treatment targeting aTreg cells and M2 macrophages hampers their positive-feedback loop inducing each other, leading to enhanced T-cell populations (Supplementary Figure S2). Our results showed that, after the combined treatment, the frequency of tumour-infiltrating aTreg cells was lower than that induced by blockage of aTreg cells alone (Figures 5Aa and Ba; 9.85 ± 2.05% vs. 17.30 ± 3.54%), while the M2 macrophage content was also decreased to 21.5 ± 2.12% from 37.80 ± 2.55% of single M2 macrophage depletion (Figures 5Ab and Bb), indicating an effect on the feedback loop. Therefore, this combined strategy reduces suppressor cells to the least extent by targeting them directly and interfering with their interactions in the TME.

**DISCUSSION**

In this study, we show that M2-polarised macrophages in the tumour environment promote the differentiation of CD4+ CD25+ T cells into aTreg cells. In turn, these generated aTreg cells skew the differentiation of monocytes toward M2 macrophages, forming a positive-feedback loop. This M2 macrophage-aTreg cell loop contributes to immunosuppression and is associated to advanced clinical stage and poor survival in LSCC patients.

Tumour-infiltrating Treg cells promote local tumour growth by exerting immunosuppressive effects against tumour-associated antigen (TAA) T-cell responses (Curiel et al., 2004; Sato et al., 2005; Khazaei and von Boehmer, 2006; Zou, 2006; Liu et al., 2009). Yet Treg cells have been reported to be both negative and positive prognostic factors for cancers (Curiel et al., 2004; Wolf et al., 2005; Badoual et al., 2006; Hiraoka et al., 2006; Fu et al., 2007; Frey et al., 2010; Bron et al., 2013; Jie et al., 2015; Kindt et al., 2017). This contradiction regarding the role of Treg cells in cancer prognosis might because Treg cells in humans are functionally heterogeneous, and include suppressive and non-suppressive cell subsets (Miyara et al., 2009; DeLeeuw et al., 2012). Tumour-infiltrating suppressive aTreg cells were proved to be the real Treg subset controlling the poor prognosis of cancers (Sun et al., 2014, 2015, 2016; Sato et al., 2016). Recently, to evoke antitumour immunity in vivo, we blocked tumour trafficking of aTreg cells using a CCR4 antagonist, which led to inhibition of tumour growth and prolonged survival (Sun et al., 2016). However, the effect was not satisfactory, indicating that a single target in the treatment of HNSCC has a limitation.

Macrophages are a major component of the leukocyte infiltrate in tumours and considered to be another crucial mediator of tumour immunity (Balkwill and Mantovani, 2001; Qian and Pollard, 2010; Noy and Pollard, 2014). Different types of macrophages, including M1 and M2, are of high scientific importance for subtyping. M1 macrophages are immunostimulatory and anti-tumoural, while M2 macrophages are immunosuppressive and pro-tumoural. Thus far, studies have been mainly based on whole intratumoural macrophages and have not reached a consensus on their effects on tumours. In the thyroid, lungs, oral cavity, and hepatocellular cancers, an increased macrophage density is associated with poor survival (Marcus et al., 2004; Chen et al., 2005; Ryder et al., 2008; Zhu et al., 2008). However, in pancreatic and gastric cancers, high intratumoural macrophages correlate with increased survival (Kim et al., 2008; Wang et al., 2011). The causes of such conflicting results may lie in the fact that whole macrophages were taken into account and not the subsets of
Figure 5. Combined targeting of aTreg cells and M2 macrophages has a superior effect on deregulating the two intratumoural populations and significantly increasing antitumour immunity in mice. (A) Representative plots of the frequency of aTreg cells (a), M2 macrophages (b), and CD4⁺ and CD8⁺ T cells (c) in the tumour masses of the control, CCR4 antagonist-, GdCl₃-, and CCR4 antagonist + GdCl₃-treated groups. (B) Comparison of the percentage of aTreg cells (a), M2 macrophages (b), and CD4⁺ and CD8⁺ T cells (c and d) in the tumour tissues of the various groups. (C) Production of IFN-γ, IL-2, and TNF-α by intratumoural CD4⁺ T cells was detected by intracellular staining. Representative data of each cytokine are shown (a–c). (D) The frequency of Th1 cytokine (IFN-γ, IL-2, and TNF-α)-positive cells was calculated as the percentage of CD4⁺ T cells. Histograms show the frequencies of each Th1 cell subset in the four groups (a–c). Data in B and D represent the mean ± s.d. (n = 5). *P < 0.05, **P < 0.01 compared with the control. Statistical comparisons were performed using the Student’s t-test. M2, type 2 macrophages.
macrophages, especially M2, because the phenotype of macrophages can vary in different tumour types. In our study, the tumour-infiltrating macrophages in LSCC tissues were a distinct M2-polarised population and negatively associated with overall survival.

Different types of malignant tumours, including HNSCC, have various abilities to polarise macrophages, which is characterised by the expression of M2 macrophage surface markers and the ability to secrete M2 cytokines. Our study showed that, compared with HNSCC cell lines SNU46 and HONE1, laryngeal carcinoma cell

Figure 6. Blockade of aTreg cell trafficking combined with depletion of M2 macrophages exerts a marked inhibitive effect on tumour growth. (A) Representative photographs of tumour-bearing mice in control, CCR4 antagonist-, GdCl3- and CCR4 antagonist + GdCl3-treated groups at 4 weeks after tumour cell injection. (B) Tumour sizes were measured every 4 days after tumour cell injection. The tumour volume was calculated using the formula: width² × length × 0.5 (length > width). *P<0.05, **P<0.01. (C) Survival is depicted as a percentage of surviving mice on the indicated day after tumour cell injection. Statistical comparisons were performed using the Kaplan–Meier method. n = 6; *P<0.05, **P<0.01. (D and E) Four weeks after tumour cell injection, the tumour mass was excised and its weight was measured. *P<0.05, **P<0.01. (F) Comparison of the mean spleen weight among groups assessed at 4 weeks after tumour cell injection. *P<0.05. (G and H) Immunohistochemical staining (original magnification: × 200) of the tumour mass in the four groups (n = 5 for each group) using an anti-CD3 mAb. The number of T cells was manually counted and is presented as the ratio of T cells to non-T cells including tumour cells. Data are the mean ± s.d. of CD3 ratios. *P<0.05, **P<0.01. (I) The frequency of CD4⁺ or CD8⁺ T cells was determined by flow cytometry and calculated as the percentage of CD4⁺ or CD8⁺ cells in splenocytes from mice with no statistical significance among the four groups (P>0.05).
line SNU899-derived TSNs had the most significant influence on the differentiation of monocytes toward M2 macrophages, resulting in the highest expression of M2-specific marker and cytokine levels. The varied degree of polarisation may lead to a difference in the function of macrophages, such as their interaction with lymphocytes (Biswas and Mantovani, 2010).

Our study demonstrated that the high intratumoral M2 macrophage density was positively correlated with the elevated intratumoral Foxp3⁺ Treg population. Accumulation of M2 macrophages and/or Foxp3⁺ Treg cells in LSCC tissue is associated to advanced T stage and poor survival. We hypothesised that these cells cooperate with each other to enhance immunosuppression in tumours. Our in vitro results revealed that TSN-exposed macrophages with the most typical M2 features had the strongest ability to induce Foxp3⁺ Treg cells by acting on responder PBMCs. To identify whether the induced Tregs were converted from CD4⁺ CD25⁺ T cells, rather than expansion of previous Tregs in the culture system, we replaced the responder cells with CD4⁺ CD25⁺ T cells and observed clear upregulation of Treg cell surface antigens by flow cytometry, thereby confirming their interactions. Previous study has demonstrated that Foxp3⁺ Treg cells are composed of three phenotypically and functionally distinct subpopulations: CD45RA⁻ Foxp3⁺low rTreg cells and CD45RA⁻ Foxp3⁺low aTreg cells, both of which are suppressive in vitro, and cytokine-secreting CD45RA⁺ Foxp3 low nonsuppressive T cells (Miyara et al., 2009). Based on this classification of human Tregs, our study provided evidence to support the notion of heterogeneous Treg subsets in HNSCC patients (Sun et al., 2014, 2015, 2016). We showed that aTreg cells, as the predominant cell population among tumour-infiltrating Foxp3⁺ Treg cells, accelerate disease progression by suppressing TAA immunity in patients with HNSCC (Sun et al., 2016; Wei et al., 2016). To determine whether TSN-exposed M2-like macrophages contribute to an increase in aTreg cells, we analysed the subsets of induced Treg cells. Interestingly, the aTreg cell frequency was dominantly increased in the suppressive Treg-cell population, indicating that the Treg cells induced by M2-like macrophages can directly mediate an inhibitory effect on tumour immunity.

Conversely, to examine the effect of aTreg cells on macrophage functions in the context of tumour-induced immunosuppression, we added TSNs to the co-culture system to mimic the tumour microenvironment (TME). Interestingly, aTreg cell-effected monocytes expressed significantly higher levels of an M2-specific marker in the TSNs compared with the medium alone, whereas single TSNs had only a marginal effect on M2 marker induction within the specific time. These results indicated that TSNs have a good promotion effect on M2 macrophage induction by aTreg cells. The reverse process connected the formation of M2 macrophages and aTreg cells to a positive-feedback loop that may contribute to an increase of their number in tumours. Therefore, this biological mechanism can serve as an explanation for the positive correlation between aTreg cells and M2 macrophages in LSCC tissue.

To validate the positive-feedback relationship between M2 macrophages and aTreg cells and its importance in vivo, we targeted the two populations individually in a tumour-bearing mouse model. As a result, depletion of intratumoural M2 macrophages simultaneously attenuated the intratumoural aTreg cell frequency, whereas blockade of aTreg cell tumour trafficking indirectly decreased the percentage of intratumoural M2 macrophages. These data indicate that it is imperative to further investigate combined strategies to interfere with both M2 macrophages and aTreg cells in the TME.

Indeed, targeting M2 macrophages and aTreg cells simultaneously had a superior effect on regulating the two cell populations. Both aTreg cells and M2 macrophages have a key role in subversion of anti-tumour immunity. The former can suppress TAA-T-cell responses by cell contact, while the latter have a poor antigen-presenting capacity and suppress T-cell activation and proliferation by releasing prostaglandins, IL-10, and TGF-β (Kambayashi et al., 1995; Maeda et al., 1995; Locher et al., 1999; Sakaguchi et al., 2009). In mice, we found that the combined strategy was more efficient than single targeting for inhibition of tumour growth and prolongation of survival. The efficiency is derived from deregulation of antitumour immunity because the proportions of CD4⁺ and CD8⁺ T cells and Th1 cells were increased significantly. Furthermore, we found that this strategy had no significant influence on the peripheral immune status, thus indicating greater potential therapeutic implications.

This combined targeting strategy, based on the theory of the M2 macrophage-aTreg cell positive-feedback loop, may offer new approaches to overcome the barriers of immunosuppression in the TME. Various options can be provided for the specific therapeutic program, including blocking tumour trafficking of macrophages/Treg cells using CSF1R/CCR4 antagonists, respectively (Sugiyama et al., 2013; Ries et al., 2014; Kurose et al., 2015), ligation of GITR to down-regulate Foxp3 expression and reduce production of IL-10 by Treg cells (Schae et al., 2013), and re-educating M2 macrophages to an M1 phenotype using Toll-like receptor 3 ligands or STING agonists (Shime et al., 2012; Downey et al., 2014; Baird et al., 2016). A rational combination of the above methods may exert an unexpected antitumour effect in LSCC treatment.

In summary, our study suggests an important role of the positive-feedback loop between tumour-infiltrating M2 macrophages and aTreg cells in tumour progression. This positive-feedback loop is essential to maintain or promote immunosuppression in the TME and could be a potential therapeutic target against tumour progression.

ACKNOWLEDGEMENTS

This work was supported by grants from the Natural Science Foundation of Guangdong Province (2016A030301153, 2014A030 31031, and 2016A030313257), the Science and Technology Planning Project of Guangdong Province (2014A020212141), the Natural Science Foundation of China (81602365, 81670902, and 81470674), the Medical Scientific Research Foundation of Guangdong Province (A2017216), and the Guangzhou Key Laboratory of Otorhinolaryngology Head and Neck Surgery (201605030003).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Alhamarneh O, Amarnath SM, Stafford ND, Greenman J (2008) Regulatory T cells: what role do they play in antitumour immunity in patients with head and neck cancer? Head Neck 30: 251–261.

Badoval C, Hans S, Rodriguez J, Peyrard S, Klein C, Aguznay NE, Mosseri V, Laccourreye O, Bruneval P, Fridman WH (2006) Prognostic value of tumour-infiltrating CD4(+) T-cell subpopulations in head and neck cancers. Clin Cancer Res 12: 465–472.

Baird JR, Friedman D, Cottam B, Dubensky TJ, Kanne DB, Bambina S, Bahjat K, Crittenden MR, Gough MJ (2016) Radiotherapy combined with Novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res 76: 50–61.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539–545.

Begum S, Westra WH (2008) Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol 32: 1044–1050.
Biswa SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889–896.

Bron L, Jandus C, Andrejevic-Blant S, Speiser DE, Monnier P, Romero P, Rivals JP (2013) Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 132: E85–E93.

Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 953–964.

Curiel TJ, Coukos G, Zou LH, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burrow M (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.

DeLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18: 3022–3029.

Downey CM, Aghaie M, Schwendener RA, Jirik FR (2014) DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2’3’-cGAMP, induces M2 macrophage repolarization. PLoS One 9: e99988.

Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33: 3293–3304.

Frey DM, Droesser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oerlil D, Kettelhack C, Terracciano L, Tonnolo I. (2010) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126: 2635–2643.

Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328–2339.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3(+) regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423–5434.

Jiang W, Sun R, Wei HM, Tian ZG (2005) Toll-like receptor 3 ligand derived hyaluronan induces formation of immunosuppressive T cell populations: cancer as a paradigm. Nat Med 11: 942–949.

Kambayashi T, Alexander HR, Fong M, Strassmann G (1995) Potential mechanism involving IL-10. Cancer Res 55: 587–595.

Kascal AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163: 6251–6260.

Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraiishi A (1995) TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 155: 4926–4932.

Mantovani A, Sozani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549–555.

Mantovani A, Locati M (2013) Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 33: 1478–1483.

Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Teknos TN (2004) Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma—The impact of tumor-associated macrophages. Cancer 101: 2779–2787.

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D (2009) Functional Delineation and Differentiation Dynamics of Human CD4(+) T Cells Expressing the FoxP3 Transcription Factor. Immunity 30: 899–911.

Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41: 49–61.

Qian BZ, Yang HY, Cai LL, Qu H, Sun H, Zhang H (2015) Anti-CCR4 mAb selectively depletes effector-type FoxP3(+) T cells in treated head and neck cancer patients suppress NK cell cytotoxicity and tumor-infiltrating lymphocytes and a high CD8(+) CD25(+) regulatory T cell ratio abrogate antitumor immunity. J Immunol 195: 1833–1843.

Ries CH, Carnarville MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel JP, Feuerbacher F, Klaman I, Jotes T, Jucknichske U, Scheibich S, Kaluza K, Gorr IH, Walz A, Abirai K, Cassier PA, Sica A, Gomez-Baca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttiger D (2014) Targeting tumor-associated macrophages with anti-CSF1-R antibody reveals a strategy for cancer therapy. Cancer Cell 25: 846–859.

Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15: 1069–1074.

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Okura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S (2016) Two FOXP3(+) CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22: 679–684.

Sakaguchi S, Wing K, Onishi Y, Prieto-Martín P, Yamaguchi T (2009) Regulatory T cells: how do they suppress immune responses? Int Immunol 21: 1105–1111.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Prossina D, Gnjatic S, Ambrosone C, Kepner J, Odanski T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8(+)/regulatory T cell ratio is associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 17077–17082.

Schalm SW, Weisman MP, Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Hirohashi S, Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T (2009) Differentiation Dynamics of Human CD4(+)FOXP3 Transcription Factor. Immunity 30: 899–911.

Shimizu M, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Ikawara Y, Tahara H, Inoue N, Seya T (2012) Toll-like receptor 3 ligand signals converging tumor-supporting myeloid cells to tumorigenic effectors. Proc Natl Acad Sci USA 109: 2066–2071.

Sugiyama D, Nishikawa H, Maeda Y, Nishioha M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jäger E, Sakaguchi S (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3(+) CD4(+) regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 110: 17945–17950.

Sun W, Li WJ, Fu QL, Wu CY, Lin JZ, Zhu XL, Hou WJ, Wei Y, Wen YH, Wang YJ (2015) Functionally distinct subsets of CD4(+) regulatory T cell.
cells in patients with laryngeal squamous cell carcinoma are indicative of immune deregulation and disease progression. Oncol Rep 33: 354–362.
Sun W, Li WJ, Wei FQ, Wong TS, Lei WB, Zhu XL, Li J, Wen WP (2016) Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget 7: 37714–37727.
Sun W, Li BJ, Wu CY, Zhong H, Wen WP (2014) CD45RA(-)Foxp3(high) but not CD45RA(+)Foxp3(low) suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Canc Res 33: 35.
Wang B, Xu DZ, Yu XJ, Ding T, Rao HL, Zhan YQ, Zheng LM, Li L (2011) Association of intra-tumoral infiltrating macrophages and regulatory t cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol 18: 2585–2593.
Wei FQ, Sun W, Wong TS, Gao W, Wen YH, Wei Y, Wen WP (2016) Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. J Exp Clin Cancer Res 35: 18.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)